PMID- 12915593
OWN - NLM
STAT- MEDLINE
DCOM- 20030915
LR  - 20151119
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 21
IP  - 16
DP  - 2003 Aug 15
TI  - CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly 
      patients with aggressive non-Hodgkin's lymphoma.
PG  - 3041-50
AB  - PURPOSE: To investigate whether the relative dose-intensity of cyclophosphamide, 
      doxorubicin, vincristine, and prednisone (CHOP) chemotherapy could be improved by 
      prophylactic administration of granulocyte colony-stimulating factor (G-CSF) in 
      elderly patients with aggressive non-Hodgkin's lymphoma (NHL). PATIENTS AND 
      METHODS: Patients aged 65 to 90 years (median, 72 years) with stage II to IV 
      aggressive NHL were randomly assigned to receive standard CHOP every 3 weeks or 
      CHOP plus G-CSF every 3 weeks on days 2 to 11 of each cycle. RESULTS: In 389 
      eligible patients, the relative dose intensities (RDIs) of cyclophosphamide 
      (median, 96.3% v 93.9%; P =.01) and doxorubicin (median, 95.4% v 93.3%; P =.04) 
      were higher in patients treated with CHOP plus G-CSF. The complete response rates 
      were 55% and 52% for CHOP and CHOP plus G-CSF, respectively (P =.63). The 
      actuarial overall survival at 5 years was 22% with CHOP alone, compared with 24% 
      with CHOP plus G-CSF (P =.76), with a median follow-up of 33 months. Patients 
      treated with CHOP plus G-CSF had an identical incidence of infections, with World 
      Health Organization grade 3 to 4 (34 of 1,191 cycles v 36 of 1,195 cycles). Only 
      the cumulative days with antibiotics were fewer with CHOP plus G-CSF (median, 0 v 
      6 days; P =.006) than with CHOP alone. The number of hospital admissions and the 
      number of days in hospital were not different. CONCLUSION: In elderly patients, 
      G-CSF improved the RDI of CHOP, but this did not lead to a higher complete 
      response rate or better overall survival. G-CSF did not prevent serious 
      infections.
FAU - Doorduijn, J K
AU  - Doorduijn JK
AD  - Department of Hematology, Erasmus Medisch Centrum Rotterdam, PO Box 2040, 3000 CA 
      Rotterdam, the Netherlands. j.doorduijn@erasmusmc.nl
FAU - van der Holt, B
AU  - van der Holt B
FAU - van Imhoff, G W
AU  - van Imhoff GW
FAU - van der Hem, K G
AU  - van der Hem KG
FAU - Kramer, M H H
AU  - Kramer MH
FAU - van Oers, M H J
AU  - van Oers MH
FAU - Ossenkoppele, G J
AU  - Ossenkoppele GJ
FAU - Schaafsma, M R
AU  - Schaafsma MR
FAU - Verdonck, L F
AU  - Verdonck LF
FAU - Verhoef, G E G
AU  - Verhoef GE
FAU - Steijaert, M M C
AU  - Steijaert MM
FAU - Buijt, I
AU  - Buijt I
FAU - Uyl-de Groot, C A
AU  - Uyl-de Groot CA
FAU - van Agthoven, M
AU  - van Agthoven M
FAU - Mulder, A H
AU  - Mulder AH
FAU - Sonneveld, P
AU  - Sonneveld P
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
CIN - J Clin Oncol. 2005 Jul 20;23(21):4797-9; author reply 4799-800. PMID: 16034060
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
MH  - Cyclophosphamide/*administration & dosage
MH  - Doxorubicin/*administration & dosage
MH  - Female
MH  - Granulocyte Colony-Stimulating Factor/*administration & dosage
MH  - Humans
MH  - Lymphoma, Non-Hodgkin/*drug therapy
MH  - Male
MH  - Prednisone/*administration & dosage
MH  - Quality of Life
MH  - Treatment Outcome
MH  - Vincristine/*administration & dosage
EDAT- 2003/08/14 05:00
MHDA- 2003/09/16 05:00
CRDT- 2003/08/14 05:00
PHST- 2003/08/14 05:00 [pubmed]
PHST- 2003/09/16 05:00 [medline]
PHST- 2003/08/14 05:00 [entrez]
AID - JCO.2003.01.076 [pii]
AID - 10.1200/JCO.2003.01.076 [doi]
PST - ppublish
SO  - J Clin Oncol. 2003 Aug 15;21(16):3041-50. doi: 10.1200/JCO.2003.01.076.